Fourteen years in medical content.
One process we'll run for you.
The receipts below are real. Owner-verified analytics, named bylines, peer-reviewed archives. But the real pitch is simpler: send us a brief. Every piece you get back has been through three to four credentialed people before it reaches you.
Fourteen years of pattern recognition, turned into a process.
Fast. Reliable. Accurate even in the age of AI. That's the only promise this page is trying to back up.
Chris and Alex have been building in health, wellness, and medical content since 2012. Along the way they broke it, rebuilt it, watched Google torch the category's shortcut shops, and survived every core update in the window. What came out the other side is a repeatable editorial process: topic to credentialed subject-matter expert, expert to independent peer reviewer, reviewer to managing editor, editor to YMYL flag. Three to four credentialed people touch every piece before you see it. That is why the charts below aren't flukes, and why the only thing we're asking you to do at the end of this page is send us a brief.
- 01
Health Clinics
Multi-location medical practices, specialty groups, dental & concierge.
- 02
Digital Health Brands
DTC supplement, OTC, device, wearable & app brands.
- 03
Digital Health Media
Consumer health publishers, comparison sites & review media.
- 04
Treatment Centers
Addiction, behavioral health, IOP/PHP & residential programs.
- USARx.com
- Diabetic.org
- Pharmacists.org
- Allergies.org
0 → 1.5M organic sessions / mo.
14,000 peer-reviewed articles over 11 years. The site that became the playbook for Experts Ink.
Chris Riley ran SEO and editorial at USARx.com from 2012 through 2023. Across 11 years his team shipped 14,000 peer-reviewed articles, drug monographs, and condition pages, growing the property from zero to a 1.5M organic sessions / mo peak in 2023. USARx is where Chris became a medical writer himself, where he first worked with Alex (then doing content at GoodRx), and where the in-the-trenches version of the Experts Ink playbook was built. Chris departed USARx in 2023 and stood up Experts Ink around everything the 11-year run had proven.
- Flagship · 2012-2023
- 14,000 articles
- 1.5M sessions peak
- Organic sessions / mo
- 1.5M (2023 peak)
- Articles published (peer-reviewed)
- 14,000+
- Ranked keywords (top-10)
- 48,000+
- Google core-update survival (tenure)
- 7 / 7
“USARx is where I learned what healthcare content actually is. Eleven years, 14,000 articles, one standard of evidence: real clinicians, named, on every piece. That's the playbook I took into Experts Ink.”
$0 → six-figure monthly organic revenue.
A DTC diabetic-sock brand Experts Ink built the podiatrist-reviewed content layer for over 2+ years.
Circufiber is a direct-to-consumer copper-fiber compression sock brand targeting diabetic foot, neuropathy, and circulation patients. Experts Ink ran content for the brand for 2+ years: podiatrist-reviewed explainers on diabetic foot ulcers, venous insufficiency, and plantar neuropathy, plus PDP copy and a medical-claim audit. That clinical foundation gave the brand a PDP trust curve DTC competitors in the compression category never matched.
- Client engagement · DTC
- Podiatrist-reviewed
- 2+ year retainer
- Organic sessions / mo (peak)
- 148k
- Podiatrist-reviewed articles
- 260+
- Organic revenue / mo (peak)
- Six figures
- Engagement length
- 2+ years
“Compression socks is the most commoditized corner of DTC. The category gets won with one thing competitors don't have: a real podiatrist on every explainer. The trust curve is the asset, not the traffic.”
8k → ~720k peak sessions / mo.
A CDCES-reviewed diabetes publisher that went head-to-head with Healthline on hundreds of high-intent queries.
Diabetic.org is a consumer health property Chris built and ran personally, covering type-1, type-2, GLP-1s, insulin regimens, CGMs, and diabetic complications. Every clinical page was reviewed by a Certified Diabetes Care and Education Specialist (CDCES) or a board-certified endocrinologist. Three years of patient, peer-reviewed publishing built a content moat that ranked #1 against WebMD and Healthline on dozens of diabetes topics patients actually search. Part of a portfolio Chris exited in 2023.
- Owned property
- CDCES-reviewed
- Acquired 2023
- Organic sessions / mo (peak)
- ~720k
- CDCES / endocrinologist-reviewed articles
- 2,400+
- Ranked #1 vs Healthline / WebMD
- Dozens of terms
- Years operated
- ~3
“Same playbook USARx ran, narrower niche. Real CDCES bylines, real peer review, years of patience. Volume shortcuts didn't beat it. Nobody's shortcut did.”
0 → ~520k peak sessions / mo.
Built into the highest-ranking independent PharmD authority site on the open web, then acquired.
Pharmacists.org is a publisher Chris built from zero covering PharmD career paths, state licensure, clinical specialization, and pharmacist-authored consumer drug content. Every clinical piece was written or reviewed by a board-certified PharmD with a linked-out professional profile and conflict-of-interest disclosure. By exit in 2023 it was the highest-ranking independent pharmacist authority site on the open web. Part of the portfolio Chris sold that year.
- Owned property
- PharmD-reviewed
- Acquired 2023
- Organic sessions / mo (peak)
- ~520k
- PharmD-reviewed articles
- 1,800+
- Top-3 rankings (PharmD career queries)
- 400+
- Years operated
- ~3
“If you want to rank for what a pharmacist searches for, you need a pharmacist on the byline. That was the whole rule. That's the rule that got acquired.”
A freelance medical writer isn't really your competition.
Another agency with this process is.
Most prospects compare us against an individual medical writer on Fiverr, Upwork, Contra, or a referral. Fair. Here's the honest side-by-side. We are not cheaper. We are not faster per piece. We are the only option if the work has to hold up to a patient, a regulator, a journalist, and a Google core update all at once.
- One person. One pass. One set of eyes on the piece.
- Credentials are a line on a profile. No verifiable reviewer, no named license number, no linked-out professional page.
- Research is Google plus a few citations. Primary sources (PubMed, trial registries, FDA labels) are rare.
- AI use is opaque. You are trusting the profile photo and the star rating.
- No second-expert peer review. No editorial QA pass. No YMYL or legal flag before publish.
- Turnaround is whenever the freelancer can. Capacity ends where their week ends.
- No paper trail. When a journalist, regulator, or your legal team asks where a claim came from, there is nothing to hand over.
- Zero continuity across a core update. If the piece tanks, the freelancer is already on the next gig.
- Three to four credentialed people on every piece: subject-matter author, independent peer reviewer, managing editor, YMYL / legal flag.
- Reviewers are named, licensed, and linked out. Board certifications verified. No rented badges. No ghost bylines.
- Primary sources only. Every clinical claim tracks back to a peer-reviewed study, regulatory filing, or professional-society guideline, logged per piece.
- AI is used for research acceleration and QA. Never authorship. Workflow is auditable and disclosed to the client.
- Mandatory second-expert peer review. Editor pass. YMYL / legal flag before anything ships.
- Median first draft in 8 business days. Median final in 10. Retainer-backed capacity, not one person's calendar.
- Full paper trail: author, reviewer, sourcing log, revision history, disclosure block. Regulator-ready on request.
- A process refined across 14 years and tested against every Google core update since 2012, HCU 2023 included.
28+ client engagements since the portfolio exit. Names withheld at client request.
Everything above was the build. This is the current business. Since 2023, Experts Ink has run this process for treatment centers, behavioral health programs, multi-location clinics, specialty pharmacies, DTC brands, telehealth, and consumer-health publishers across the US. Most don't want their editorial strategy on a competitor's desk. Fair.
You've seen the receipts we can show. The rest live behind the brief form. Send us a brief and we'll tell you, on the first call, whether we've solved your exact problem before. If we have, that's the conversation worth having. If we haven't, we'll say so.
Give us a brief.
We'll send back a sample.
A topic, a keyword, or a full outline, whatever you have. Within three business days we'll come back with a sample outline for the piece, a quick audit of your existing content, related recommendations, and a scoped pilot quote. The pilot is the sample article itself.
- · A topic or keyword is a valid brief
- · 3 business days
- · No meeting required